big ideas for global investors Search
   Members       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   

TSX Investing Ideas: TSX Top Traders: (BB), (BTO), (MYG), (EXN)

Category: Investment

Visit: B2Gold Corp.

New York, New York - March 18, 2013 ( newswire) staff:, an investor research portal specializing in sector research for independent investors reports on the top traders on the TSX for March 18th, 2013.

Research In Motion Limited (TSX:BB) trading at $15.570 gained $0.170 or 1.10% on a high volume of 3,570,758 shares, making it today's top trader on the TSX.

Blackberry continues to moved upwards as sales of the new Z10 continue to rise as well as the anticipated US release of the new Blackberry phones later this week. Newswire

B2Gold Corp., (TSX:BTO) trading at $3.170 went down $-0.010 or -0.31% on a volume of 3,273,264 shares.

B2Gold Corp. announced that it will release its 2012 fourth quarter results and full year 2012 financial results before the North American markets open on Thursday March 28 th, 2013.

B2Gold executives will host a conference call to discuss the results on Thursday March 28 th, 2013 at 10:00 am PST / 1:00 pm EST. You may access the call by dialing the operator at 416-340-8527 or toll free 877-440-9795 prior to the scheduled start time or, you may listen to the call via webcast by clicking

MethylGene Inc., (TSX:MYG) trading at $0.150 dropped $-0.030 or -16.67% on a volume of 3,213,884 shares.

MethylGene Inc. today reported topline results from its human efficacy trial (Trial 290-005) with MGCD290, a novel antifungal agent targeting the fungal enzyme, Hos2. Trial 290-005 was a randomized, multicenter, double-blind, placebo-controlled trial designed to test whether MGCD290, in combination with fluconazole, was superior to fluconazole alone in patients with moderate-to-severe vulvovaginal candidiasis.

The study showed no statistically significant benefit of MGCD290 plus fluconazole compared to fluconazole alone. There were no serious treatment-related adverse events and non-serious adverse events were evenly distributed between treatment groups. This clinical trial was conducted across nineteen sites in the USA and enrolled 171 patients with positive fungal cultures in their vaginal fluid at baseline. Detailed data will be presented at a future meeting.

Excellon Resources Inc., (TSX:EXN) trading at $0.420 lowered by $-0.005 or -1.18% on a volume of 3,194,218 shares.

Excellon Resources Inc., a mineral resource company, engages in the acquisition, exploration, development, and mining of mineral properties primarily in Mexico. It primarily explores for silver, lead, and zinc ores. The company owns a 100% interest in the Platosa property covering a total area of 40,864 hectares located in northeastern Durango States. It also has interests in the Miguel Auza property covering a total area of 41,000 hectares of under explored land in northern Zacatecas, as well as in the DeSantis Project situated near Timmins, Ontario and the Beschefer Project, located in northwestern Quebec.

About TSX

About is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .

Follow on Twitter!/Investorideas

Follow on Facebook

Follow News on at

Sign up for the free investor news and stock alerts at

Become an Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

800-665-0411 - Source -

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner


Investor Ideas © 2000 - 2015®, ECON


login | logout | about us | contact | disclaimer / disclosure |
partners / links | job search | privacy policy |
advertise | trade | sitemap |